All lobbying filings

HOOPER, LUNDY & BOOKMAN, P.C.

HOOPER, LUNDY & BOOKMAN, P.C. filed a Q4 report for BRAINFUTURES on January 20, 2026, reporting $40,000 in lobbying income.

Lobbying for BRAINFUTURES · Nonprofit advocate for therapeutic treatments for mental health and substance use disorder

All filings by HOOPER, LUNDY & BOOKMAN, P.C. · Everything BRAINFUTURES has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$40,000

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Lobbyists on this filing 1

LISA LAYMAN New on this filing

Previously held: SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Issues related to a pathway for FDA approval of psychedelic drugs and therapies; Issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; Issues related to medical adoption of and access to psychedelic drugs and therapies, including reimbursement and workforce; S. 331 - HALT Fentanyl Act, provisions related to research.; H.R. 3944 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, funding and report language related to psychedelic research.

Medical/Disease Research/Clinical Labs

Issues related to a pathway for FDA approval of psychedelic drugs and therapies; Issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies, including reimbursement and workforce; Issues related to medical adoption of and access to psychedelic drugs and therapies; S. 331 - HALT Fentanyl Act, provisions related to research.

Budget/Appropriations

H.R. 3944 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, funding and report language related to psychedelic research, H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, support for psychedelic therapies for treatment of mental health and substance use disorders.

Veterans

H.R. 3944 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, funding and report language related to psychedelic research, H.R.2623 - Innovative Therapies Centers of Excellence Act of 2025.

Bills named in this filing 5

S. 331
HALT Fentanyl Act
H.R. 3944
Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026
H.R. 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S. 2587
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
H.R. 2623
Innovative Therapies Centers of Excellence Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.